Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9
- Drug Des Devel Ther. 2018 Oct 9;12:3357-3368. doi: 10.2147/DDDT.S177126.
- 1. Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Educational Ministry of China, School of Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China, [email protected]; [email protected].
- 2. Department of Drug Development, Tianjin Kangzhe Pharmaceutical Company, Ltd., Tianjin, People's Republic of China.
- 3. Department of Blood Transfusion, General Hospital, Tianjin Medical University, Tianjin, People's Republic of China.
- 4. Department of Clinical Laboratory, General Hospital, Tianjin Medical University, Tianjin, People's Republic of China.
Background: Tyroserleutide (YSL) inhibits the growth and metastasis of human hepatocellular carcinoma (HCC). This paper studied the effect of YSL on metastasis of human HCC and investigated its mechanisms.
Methods: In vivo, experimental lung metastasis models of human HCC SK-HEP-1 cells in nude mice were established, and In vitro, the proliferation, adhesion and invasion of SK-HEP-1 cells were detected.
Results: In vivo, YSL significantly inhibited the metastasis of human HCC. In vitro, YSL significantly inhibited the proliferation, adhesion and invasion of SK-HEP-1 cells. Through analyses with Reverse transcription PCR (RT-PCR) and Western blot, we observed that YSL significantly inhibited the expressions of ICAM-1 in SK-HEP-1 cells. Through RT-PCR, Western blot and zymography methods, YSL was discovered to decrease the mRNA level, protein expression and activity of MMP-2 and -9 in SK-HEP-1 cells.
Conclusion: We concluded that YSL could inhibit tumor growth and metastasis of human HCC SK-HEP-1 cells.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
-